The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Aurora Kinase Inhibitors: Current Status and Outlook
Open accessAbstract
The Aurora kinase family comprises of cell cycle-regulated serine/threonine kinases important for mitosis. Their activity and protein expression are cell cycle regulated, peaking during mitosis to orchestrate important mitotic processes including centrosome maturation, chromosome alignment, chromosome segregation, and cytokinesis. In humans, the Aurora kinase family consists of three members; Aurora-A, Aurora-B, and Aurora-C, which each share a conserved C-terminal catalytic domain but differ in their sub-cellular localization, substrate specificity, and function during mitosis. In addition, Aurora-A and Aurora-B have been found to be overexpressed in a wide variety of human tumors. These observations led to a number of programs among academic and pharmaceutical organizations to discovering small molecule Aurora kinase inhibitors as anti-cancer drugs. This review will summarize the known Aurora kinase inhibitors currently in the clinic, and discuss the current and future directions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation
Zhou, H., Kuang, J., Zhong, L., Kuo, W.-L., Gray, J., Sahin, A., Brinkley, B., & Sen, S. (1998) · Nature Genetics · doi:10.1038/2496 · Cited by 1,276
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers
Bischoff, J. R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3052 · Cited by 1,216
The cellular geography of Aurora kinases
Carmena, M., & Earnshaw, W. C. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1245 · Cited by 1,139
The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis
Carmena, M., Wheelock, M., Funabiki, H., & Earnshaw, W. C. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3474 · Cited by 905
Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery
Macůrek, L., Lindqvist, A., Lim, D., Lampson, M. A., Klompmaker, R., Freire, R., Clouin, C., Taylor, S. S., Yaffe, M. B., & Medema, R. H. (2008) · Nature · doi:10.1038/nature07185 · Cited by 710
Bora and the Kinase Aurora A Cooperatively Activate the Kinase Plk1 and Control Mitotic Entry
Seki, A., Coppinger, J. A., Jang, C.-Y., Yates, J. R., & Fang, G. (2008) · Science · doi:10.1126/science.1157425 · Cited by 619
Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma
Otto, T., Horn, S., Brockmann, M., Eilers, U., Schüttrumpf, L., Popov, N., Kenney, A. M., Schulte, J. H., Beijersbergen, R., Christiansen, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.005 · Cited by 573
Sampath, S. C., Ohi, R., Leismann, O., Salic, A., Pozniakovski, A., & Funabiki, H. (2004) · Cell · doi:10.1016/j.cell.2004.06.026 · Cited by 422
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase
Manfredi, M. G., Ecsedy, J. A., Meetze, K. A., Balani, S. K., Burenkova, O., Chen, W., Galvin, K. M., Hoar, K. M., Huck, J. J., LeRoy, P. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608798104 · Cited by 413
AIM-1: a mammalian midbody-associated protein required for cytokinesis
Terada, Y. (1998) · The EMBO Journal · doi:10.1093/emboj/17.3.667 · Cited by 393
Cited by
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Aurora kinases: novel therapy targets in cancers
Tang, A., Gao, K., Chu, L., Zhang, R., Yang, J., & Zheng, J. (2017) · Oncotarget · doi:10.18632/oncotarget.14893 · Cited by 382
Shah, K. N., Bhatt, R., Rotow, J., Rohrberg, J., Olivas, V., Wang, V. E., Hemmati, G., Martins, M. M., Maynard, A., Kuhn, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0264-7 · Cited by 286
Current Diagnosis and Management of Small-Cell Lung Cancer
Wang, S., Zimmermann, S., Parikh, K., Mansfield, A. S., & Adjei, A. A. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.034 · Cited by 282
Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic
Shi, J., & Mitchison, T. J. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0003 · Cited by 79
“2011, McInnes & Wyatt 2011, Bavetsias & Linardopoulos 2015).”
Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs
Heinzlmeir, S., Kudlinzki, D., Sreeramulu, S., Klaeger, S., Gande, S. L., Linhard, V., Wilhelm, M., Qiao, H., Helm, D., Ruprecht, B., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00709 · Cited by 56
Zhang, W., Xia, D., Li, Z., Zhou, T., Chen, T., Wu, Z., Zhou, W., Li, Z., Li, L., & Xu, J. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1855-z · Cited by 38
Benjaskulluecha, S., Boonmee, A., Pattarakankul, T., Wongprom, B., Klomsing, J., & Palaga, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-05929-x · Cited by 34
The RNA binding proteins LARP4A and LARP4B promote sarcoma and carcinoma growth and metastasis
Coleman, J. C., Tattersall, L., Yianni, V., Knight, L., Yu, H., Hallett, S. R., Johnson, P., Caetano, A. J., Cosstick, C., Ridley, A. J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109288 · Cited by 15
Post-transcriptional control drives Aurora kinase A expression in human cancers
Cacioppo, R., Rad, D., Pagani, G., Gandellini, P., & Lindon, C. (2024) · PLOS ONE · doi:10.1371/journal.pone.0310625 · Cited by 3
Metadata
- Authors
- Bavetsias, V., & Linardopoulos, S.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2015-12-21
- Volume
- 5
- Pages
- 278-278
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2222507697
- Cited by
- 277
- References
- 80
- FWCI
- 12.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.